Citable filing context
GILD's research view summarizes recent SEC filing context, starting with earnings from Aug 4, 2026.
| Filed | Item | Context |
|---|---|---|
| Aug 4, 2026 | earnings | Gilead Sciences reported Q2 2026 revenue of $7.8 billion and a diluted loss per share of $(8.45). |
| May 20, 2026 | debt_offering | Gilead Sciences issued $3.0 billion in 4.250%, 4.400%, 4.600%, and 4.900% senior notes due 2028, 2029, 2031, and 2034. |
| May 7, 2026 | earnings | Gilead reported Q1 2026 revenue of $7.0 billion and diluted EPS of $1.61, raising full-year guidance. |
| Aug 4, 2026 | Guidance: diluted_loss_per_share | -3.75 to -3.40 |
| Aug 4, 2026 | Guidance: non_gaap_diluted_loss_per_share | -0.65 to -0.30 |
| Aug 4, 2026 | Guidance: product_sales | 30100.00 to 30400.00 |
| Aug 6, 2026 | mda_quarterly | Gilead Sciences reported a net loss of $10.5 billion for the second quarter of 2026, primarily driven by $11.2 billion in acquired in-process research and development (IPR&D) expenses and a $1.75 billion impairment charge related to the discontinuation of the EVOKE-03 study for Trodelvy in non-small cell lung cancer. Despite these charges, total revenue grew 10% year-over-year to $7.8 billion, fueled by strong performance in the HIV portfolio, where Biktarvy sales rose 7% and Descovy sales increased 48%. The company’s aggressive expansion strategy included the acquisitions of Arcellx ($6.4 billion), Tubulis ($3.2 billion), and Ouro Medicines ($1.9 billion), which significantly impacted cash reserves and operating expenses. Gilead’s cash and cash equivalents declined to $3.2 billion as of June 30, 2026, down from $7.6 billion at year-end 2025, largely due to these acquisitions and the liquidation of the marketable debt securities portfolio. Legal risks remain a focal point for analysts, particularly regarding ongoing antitrust litigation and product liability claims involving HIV medications. While the company recently secured a favorable ruling in California state court regarding Viread and Truvada, other litigation, including Phase II antitrust claims and qui tam lawsuits, continues to pose potential financial exposure. |
| May 7, 2026 | mda_quarterly | Gilead Sciences reported a 4% increase in total revenues to $6.96 billion and a 54% rise in net income to $2.02 billion for the first quarter of 2026. This growth was primarily driven by strong HIV product sales, with Biktarvy increasing 7% to $3.36 billion and Descovy up 38% to $807 million, alongside a 37% surge in oncology drug Trodelvy sales to $402 million. Conversely, Veklury sales declined 52% to $144 million due to fewer COVID-19 hospitalizations, and Cell Therapy products (Tecartus, Yescarta) saw a 12% decrease amidst competitive headwinds. Product gross margin improved to 79.2%. Post-quarter, Gilead significantly expanded its pipeline through acquisitions, including Arcellx for anito-cel (multiple myeloma, BLA accepted), Tubulis for next-generation antibody-drug conjugates, and Ouro Medicines for OM336 (autoimmune T cell engager). These deals are projected to result in approximately $11.5 billion in acquired in-process research and development expenses in Q2 2026, leading to an expected net loss for both the second quarter and the full year. Operating cash flow increased 45% to $2.54 billion, and $2.75 billion in senior unsecured notes were repaid, though a new $1.1 billion term loan was secured. The company faces ongoing material financial risks from significant litigation, including antitrust lawsuits concerning HIV drugs and product liability claims related to older HIV treatments. |
Source: SEC EDGAR filing text and events; period Aug 4, 2026; filed Aug 4, 2026.
GILD company research is free during early access. All you need is an account, with no card required. The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay open without one.
Continue research
Follow same-sector companies and source explainers connected to the research view.
A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.
A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.
A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.
A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.